WO2003019186A3 - Assay for identifying ion channel modulators - Google Patents

Assay for identifying ion channel modulators Download PDF

Info

Publication number
WO2003019186A3
WO2003019186A3 PCT/GB2002/003927 GB0203927W WO03019186A3 WO 2003019186 A3 WO2003019186 A3 WO 2003019186A3 GB 0203927 W GB0203927 W GB 0203927W WO 03019186 A3 WO03019186 A3 WO 03019186A3
Authority
WO
WIPO (PCT)
Prior art keywords
ion channel
assay
voltage
dependence
target ion
Prior art date
Application number
PCT/GB2002/003927
Other languages
French (fr)
Other versions
WO2003019186A2 (en
Inventor
Stephen Antony Burbidge
Paula Green
David Thomas Grose
Martin Main
Helen Meadows
Jeff Pohl
Andrew Randall
Derek John Trezise
Jennings Franklin Worley Iii
Original Assignee
Glaxo Group Ltd
Stephen Antony Burbidge
Smithkline Beecham Plc
Paula Green
David Thomas Grose
Martin Main
Helen Meadows
Jeff Pohl
Andrew Randall
Derek John Trezise
Jennings Franklin Worley Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Stephen Antony Burbidge, Smithkline Beecham Plc, Paula Green, David Thomas Grose, Martin Main, Helen Meadows, Jeff Pohl, Andrew Randall, Derek John Trezise, Jennings Franklin Worley Iii filed Critical Glaxo Group Ltd
Priority to AU2002326018A priority Critical patent/AU2002326018A1/en
Publication of WO2003019186A2 publication Critical patent/WO2003019186A2/en
Publication of WO2003019186A3 publication Critical patent/WO2003019186A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides means for the skilled person to develop a high-throughput, plate-based voltage-dependence assay by transfecting a 'control' recombinant ion channel into a cell background which expresses the target ion channel. The term 'target ion channel' as used herein refers to the ion channel protein for which a modulator is sought. Development of a plate-based voltage-dependence assay will enable compounds to be ranked in terms of voltage-dependence at a very early stage in the drug discovery progression path. This invention provides the dual advantages of greatly increasing the chances of identifying voltage-dependent compounds, and of decreasing the requirement for electrophysiology. In addition, this method can be applied to help increase the signal-to-background for an ion channel assay, and to improve the ability of the user to generate stable cell lines expressing a target ion channel.
PCT/GB2002/003927 2001-08-24 2002-08-27 Assay for identifying ion channel modulators WO2003019186A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002326018A AU2002326018A1 (en) 2001-08-24 2002-08-27 Assay for identifying ion channel modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120589A GB0120589D0 (en) 2001-08-24 2001-08-24 Assay
GB0120589.7 2001-08-24

Publications (2)

Publication Number Publication Date
WO2003019186A2 WO2003019186A2 (en) 2003-03-06
WO2003019186A3 true WO2003019186A3 (en) 2003-05-08

Family

ID=9920914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/003927 WO2003019186A2 (en) 2001-08-24 2002-08-27 Assay for identifying ion channel modulators

Country Status (3)

Country Link
AU (1) AU2002326018A1 (en)
GB (1) GB0120589D0 (en)
WO (1) WO2003019186A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491803A1 (en) * 2002-06-25 2003-12-31 Serono Genetics Institute S.A. Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
US7442519B2 (en) 2002-06-25 2008-10-28 Serono Genetics Institute, S.A. KCNQ2-15 potassium channel
JP2006526389A (en) 2003-01-07 2006-11-24 ニューロームド テクノロジーズ、インク． Fluorescent T-type channel assay
CA2534438A1 (en) * 2003-07-15 2005-02-03 Chanxpress, Inc. High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
DE102006003177A1 (en) 2006-01-23 2007-08-02 Siemens Ag Apparatus and method for detecting an analyte

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055870A1 (en) * 1997-06-04 1998-12-10 A+ Science Invest Ab Detection of biologically active molecules by use of pre-activated cell-based biosensors in liquid-based separation systems
WO2001033219A2 (en) * 1999-11-02 2001-05-10 Biofocus Discovery Limited Ion channel permeability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055870A1 (en) * 1997-06-04 1998-12-10 A+ Science Invest Ab Detection of biologically active molecules by use of pre-activated cell-based biosensors in liquid-based separation systems
WO2001033219A2 (en) * 1999-11-02 2001-05-10 Biofocus Discovery Limited Ion channel permeability

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAIN M J ET AL: "MODULATION OF KCNQ2/3 POTASSIUM CHANNELS BY THE NOVEL ANTICONVULSANT RETIGABINE", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 58, no. 2, August 2000 (2000-08-01), pages 253 - 262, XP000972245, ISSN: 0026-895X *
MEADOWS H J ET AL: "FUNCTIONAL CHARACTERISATION OF HUMAN TASK-3, AN ACID-SENSITIVE TWO-PORE DOMAIN POTASSIUM CHANNEL", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 40, no. 4, March 2001 (2001-03-01), pages 551 - 559, XP000999772, ISSN: 0028-3908 *
RUKNUDIN A M ET AL: "CHARACTERIZATION OF A HUMAN MINK CHANNEL EXPRESSE IN XENOPUS OOCYTES", SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 19, no. 1-3, 1993, pages 705, XP001022126, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
GB0120589D0 (en) 2001-10-17
WO2003019186A2 (en) 2003-03-06
AU2002326018A1 (en) 2003-03-10

Similar Documents

Publication Publication Date Title
WO2005047512A3 (en) Plasmid system for multigene expression
WO2001019981A3 (en) Functional genomics using zinc finger proteins
AU2560599A (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
EP2105449A3 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
AU2002351239A1 (en) Antibody to latent membrane proteins and uses thereof
WO2001071009A3 (en) Whole-body optical imaging of gene expression and uses thereof
EP1219708A4 (en) Modulate aptamer and method for detecting target protein by using the same
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2005009409A3 (en) Controlled release preparations
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2005014797A3 (en) P16 mediated regulation of nmda receptors
WO2003019186A3 (en) Assay for identifying ion channel modulators
WO2002012470A3 (en) A member of the lysyl oxidase gene family
WO2002002738A3 (en) Host cells containing multiple integrating vectors
AU2002226019A1 (en) Spliced gene of kshv/hhv8, its promoter and monoclonal antibodies specific for lana2
WO2003020005A3 (en) Lp mammalian proteins; related reagents
WO2005033145A8 (en) Antibodies to nik, their preparation and use
AU2002222658A1 (en) Novel aggrecanase
WO2002026929A3 (en) Kini-3 motor protein and methods for its use
AU2002245255A1 (en) Regulation of target protein activity through modified proteins
WO2002074906A3 (en) Lp mammalian proteins; related reagents
WO2001096593A3 (en) Novel motor proteins and methods for their use
WO2002012541A3 (en) Novel motor proteins and methods for their use
AU5563699A (en) Analogs of udp-murnac peptides, assays and kits
AU2003282465A1 (en) Isolated mammalian membrane protein genes; related reagents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP